04th January, 2024 | By Vrushti Kothari
Agreements Support the Upcoming Launch of VEVYE®
Harrow, a leading U.S. eyecare pharmaceutical company, today announced that it has partnered with three leading healthcare technology platforms to expand U.S. availability of VEVYE® (cyclosporine ophthalmic solution) 0.1%, a patented, non‑preserved, twice-daily (BID) dosed, ophthalmic solution prescription drug based on a “water-free” semifluorinated alkane (SFA) eyedrop technology. VEVYE, uniquely dispensed in a 10 microliter drop, is the first and only cyclosporine-based product indicated for treating both signs and symptoms of dry eye disease (DED).
Harrow’s three market access partnerships for VEVYE include:
In commenting on the announcement, Mark L. Baum, Chairman and Chief Executive Officer of Harrow, said, “Harrow was founded on a commitment to patient access. Our 360-degree approach to market access for VEVYE, including these new partnerships with PhilRx, Apollo Care, and PARx, is designed to ensure that all patients who can benefit from VEVYE and who are prescribed VEVYE – can get VEVYE.
“We believe VEVYE represents an important new prescription choice in the U.S. dry eye disease market, and we are excited to streamline the prior authorization process, guiding patients through their insurance coverage and ensuring competitive pricing – with minimum hassle. Harrow’s VEVYE market access program perfectly aligns with our commitment to providing physicians and their patients with innovative and affordable ophthalmic pharmaceutical products and the Harrow team eagerly anticipates the availability of VEVYE – next week.”
Medtech Special
Artificial Intelligence Breakthroughs
Robots In Medtech
Asia Pacific
Global / International
© 2023 MM Activ Sci-Tech Communications. All rights reserved | Disclaimer